Overall market sentiment has been high on Heat Biologics Inc (HTBX) stock lately. HTBX receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With HTBX Stock Today?
Heat Biologics Inc (HTBX) stock has fallen -5.42% while the S&P 500 is higher by 0.45% as of 10:54 AM on Thursday, Dec 17. HTBX is down -$0.32 from the previous closing price of $5.90 on volume of 590,060 shares. Over the past year the S&P 500 has gained 16.46% while HTBX is higher by 73.29%. HTBX lost -$2.25 per share in the over the last 12 months.
To screen for more stocks like Heat Biologics Inc click here.
More About Heat Biologics Inc
Heat Biologics Inc is a US-based immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells that secrete tumor-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.
Click Here to get the full Stock Score Report on Heat Biologics Inc (HTBX) Stock.
